Neos Therapeutics, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016	FY2015 12 months to Dec 31, 2015
Net loss
Cash Flows From Operating Activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense
Depreciation and amortization of property and equipment
Amortization of intangible assets
Amortization of patents and other intangible assets
Amortization of patents and other intangiable assets
Changes in fair value of earnout, derivative and warrant liabilities
Amortization of patents
Amortization of senior debt issuance costs and discounts
Amortization of short-term investment purchase discounts
Loss on debt extinguishment
Deferred interest on debt
(Gain) loss on sale of equipment
Change in deferred rent
Realized gain on sale of short-term investments
Other adjustments
Amortization of senior debt fees
Changes in operating assets and liabilities:
Accounts receivable
Inventories
Deferred contract sales organization fees
Other current assets
Other assets
Accounts payable
Accrued expenses
Deferred revenue

Net cash used in operating activities

Net proceeds from sale of short-term investments
Operating lease liabilities
Net cash used in operating activities

Cash Flows From Investing Activities:
Purchases of short-term investments
Sales and maturities of short-term investments
Proceeds from sale-leaseback of equipment
Proceeds from sale of equipment
Net proceeds from issuance of stock
Capital expenditures
Intangible asset expenditures
Net cash (used in) provided by investing activities

Cash Flows From Financing Activities:
Proceeds from Deerfield debt note, net of fees
Proceeds from senior debt note
Payment of senior debt and fee
Proceeds from the issuance of common stock, net of issuance costs
Proceeds from initial public offering, net of issuance cost
Payments made on behalf of Deerfield
Payments made on borrowings
Proceeds from short-term line of credit
Payments made on short-term line of credit
Payment of debt financing costs
Increase (decrease) in cash and cash equivalents
Payments made to purchase treasury stock
Payment of payroll taxes withheld for releases of restricted stock units
Net cash (used in) provided by financing activities

(Decrease) increase in cash and cash equivalents
Cash and Cash Equivalents:
Beginning
Ending
Supplemental Disclosure of Noncash Transactions:
Acquired equipment under finance lease
Finance lease liability from purchase of equipment
Derivative liability incurred in connection with Loan and Security Agreement
Deferred debt financing costs included in accounts payable and accrued expenses
Exit Fee liability incurred in connection with Second Amendment to Facility
Derivative Liability incurred in connection with Amendments to Facility
Prepaid assets included in accounts payable and accrued expenses
Issuance of senior secured convertible notes in lieu of interest payment
Issuance of common stock upon conversion of senior secured convertible notes
Capital lease liability from sale-leaseback transactions
Beneficial conversion feature incurred on convertible notes
Deferred contract sales organization fees
Issuance of stock warrants
Exercise of Series C warrants for Series C Preferred Stock
Cashless exercise of Series C warrants from Series C financing in IPO closing
Conversion of Redeemable Preferred Stocks into Common Stock
Reclassification of Series C warrants issued with senior debt upon IPO closing
Preferred stock accretion
Preferred stock dividend

Supplemental Cash Flow Information:
Interest paid

Comments